Skip to main content
ZIM Laboratories Limited logo

ZIM Laboratories Limited — Investor Relations & Filings

Ticker · ZIMLAB ISIN · INE518E01015 LEI · 335800YPYG1O3ML66R52 BSE.NS Manufacturing
Open in API
Filings indexed 423 across all filing types
Latest filing 2025-02-19 Regulatory Filings
Country IN India
Listing BSE.NS ZIMLAB

About ZIM Laboratories Limited

https://www.zimlab.in/

ZIM Laboratories Limited is a research-driven organization specializing in the development and manufacturing of innovative drug delivery solutions. The company focuses on enhancing the efficacy and patient compliance of generic medicines through advanced formulation technologies. Its core product portfolio includes Oral Disintegrating Films (ODF), Oral Disintegrating Tablets (ODT), pellets, and taste-masked granules. Utilizing proprietary technology platforms like Thinoral, the company provides differentiated products across various therapeutic segments, including central nervous system, cardiovascular, and gastrointestinal health. ZIM Laboratories offers end-to-end services from product development and clinical trials to commercial manufacturing. The organization serves a global clientele, providing value-added generic formulations that address specific patient needs such as ease of administration and rapid onset of action.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short disclosure letter addressed to stock exchanges regarding the schedule of an Investors / Analysts Meet. It references compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events or information. The document does not contain any financial data, report content, or detailed presentation materials. It is essentially an announcement of a meeting schedule without substantive financial or operational details. Given the short length (1776 characters) and the nature of the content (disclosure of meeting schedule), this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-02-19 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short disclosure letter addressed to stock exchanges regarding the schedule of an Investors/Analysts Meet. It references compliance with SEBI Regulation 30, which pertains to disclosure obligations. The document does not contain any financial data, report content, or detailed analysis. It is essentially an announcement of a meeting schedule, not a financial report or detailed filing. The length is only 1862 characters, which is quite short and fits the pattern of a regulatory announcement rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-02-13 English
Copy of Newspaper Publication
Regulatory Filings
2025-02-11 English
Integrated Filing- Financial
Regulatory Filings
2025-02-10 English
General Updates
Investor Presentation Classification · 95% confidence The document is titled 'Q3 & 9M FY25 - Earnings Presentation' and is addressed as an earnings presentation pursuant to regulatory requirements. It contains detailed financial highlights, business model descriptions, strategic updates, and financial performance data for the third quarter and nine months of fiscal year 2025. The content includes revenue, EBITDA, PAT figures, business mix, and other operational details typically found in an investor presentation. The document is about 15,000 characters long, which is consistent with a detailed presentation rather than a brief announcement or a full annual or quarterly report. There is no indication that this is a full quarterly report (IR) with comprehensive financial statements, nor is it a simple earnings release (ER) which would be shorter and less detailed. The document is clearly a presentation prepared for investors and stakeholders to communicate financial results and business updates. Therefore, the most appropriate classification is Investor Presentation (IP).
2025-02-10 English
Financial Result Updates
Regulatory Filings
2025-02-10 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.